Winning also, Tutogen Medical (TTG) was up 75 cents, or 8.6%, to $9.47. Roth Capital upgraded the company from hold to buy Thursday morning.In other analyst action: Friedman Billings changed its price target for Valeant Pharmaceuticals (VRX - Get Report) from $26 to $22. And Merriman Curhan Ford downgraded Coley Pharmaceuticals (COLY), whose developmental program suffered Pfizer's (PFE) axe Wednesday, from buy to neutral. Valeant closed down 4 cents to $16.95, and Coley Pharmaceutical closed up 16 cents, or 4.6%, to $3.62.
Thursday's Health Winners & Losers
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts